Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA (2003) J Clin Oncol 21: 3133-40 Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE (2002) J Clin Oncol 20: 2058-66 Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Southwest Oncology Group (2002) J Clin Oncol 20: 2067-75 The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T (1999) J Exp Med 189: 1121-8 Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M (2002) J Exp Med 195: 617-24 Tapasin enhances peptide-induced expression of H2-M3 molecules, but is not required for the retention of open conformers. Lybarger L, Yu YY, Chun T, Wang CR, Grandea AG, Van Kaer L, Hansen TH (2001) J Immunol 167: 2097-105 Dendritic cell modification of neutrophil responses to infection after burn injury. Bohannon J, Cui W, Sherwood E, Toliver-Kinsky T (2010) J Immunol 185: 2847-53 STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. Rosen MJ, Chaturvedi R, Washington MK, Kuhnhein LA, Moore PD, Coggeshall SS, McDonough EM, Weitkamp JH, Singh AB, Coburn LA, Williams CS, Yan F, Van Kaer L, Peebles RS, Wilson KT (2013) J Immunol 190: 1849-58 Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. Medeiros AI, Sá-Nunes A, Turato WM, Secatto A, Frantz FG, Sorgi CA, Serezani CH, Deepe GS, Faccioli LH (2008) J Immunol 181: 8544-51 Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L (1999) J Immunol 163: 2373-7 Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection. Bohannon J, Cui W, Cox R, Przkora R, Sherwood E, Toliver-Kinsky T (2008) J Immunol 180: 3038-48 IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. Leite-De-Moraes MC, Hameg A, Pacilio M, Koezuka Y, Taniguchi M, Van Kaer L, Schneider E, Dy M, Herbelin A (2001) J Immunol 166: 945-51 CpG DNA induces a class II transactivator-independent increase in class II MHC by stabilizing class II MHC mRNA in B lymphocytes. Kuchtey J, Pennini M, Pai RK, Harding CV (2003) J Immunol 171: 2320-5 Systematic analysis of the role of CD19 cytoplasmic tyrosines in enhancement of activation in Daudi human B cells: clustering of phospholipase C and Vav and of Grb2 and Sos with different CD19 tyrosines. Brooks SR, Li X, Volanakis EJ, Carter RH (2000) J Immunol 164: 3123-31 Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, Hong S, Gadola SD, Mizutani A, Kakumanu SR, Reeves WH, Cerundolo V, Joyce S, Van Kaer L, Singh RR (2003) J Immunol 171: 2142-53 NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. Mühlen KA, Schümann J, Wittke F, Stenger S, Van Rooijen N, Van Kaer L, Tiegs G (2004) J Immunol 172: 3034-41 Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. Parekh VV, Singh AK, Wilson MT, Olivares-Villagómez D, Bezbradica JS, Inazawa H, Ehara H, Sakai T, Serizawa I, Wu L, Wang CR, Joyce S, Van Kaer L (2004) J Immunol 173: 3693-706 Enhancement of dendritic cell antigen cross-presentation by CpG DNA involves type I IFN and stabilization of class I MHC mRNA. Kuchtey J, Chefalo PJ, Gray RC, Ramachandra L, Harding CV (2005) J Immunol 175: 2244-51 CpG-B oligodeoxynucleotides inhibit TLR-dependent and -independent induction of type I IFN in dendritic cells. Liu YC, Gray RC, Hardy GA, Kuchtey J, Abbott DW, Emancipator SN, Harding CV (2010) J Immunol 184: 3367-76 Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A. Stark RJ, Choi H, Koch SR, Fensterheim BA, Lamb FS, Sherwood ER (2016) Clin Sci (Lond) 130: 451-61 Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Van Kaer L (2011) Exp Neurol 227: 19-23 Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Francica JR, Lynn GM, Laga R, Joyce MG, Ruckwardt TJ, Morabito KM, Chen M, Chaudhuri R, Zhang B, Sastry M, Druz A, Ko K, Choe M, Pechar M, Georgiev IS, Kueltzo LA, Seymour LW, Mascola JR, Kwong PD, Graham BS, Seder RA (2016) Bioconjug Chem 27: 2372-2385 Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. Hernandez A, Patil NK, Stothers CL, Luan L, McBride MA, Owen AM, Burelbach KR, Williams DL, Sherwood ER, Bohannon JK (2019) Pharmacol Res 150: 104502 Melacine: an allogeneic melanoma tumor cell lysate vaccine. Sosman JA, Sondak VK (2003) Expert Rev Vaccines 2: 353-68 Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Kim S, Lalani S, Parekh VV, Wu L, Van Kaer L (2008) Expert Rev Vaccines 7: 1519-32 Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination. Galassie AC, Goll JB, Samir P, Jensen TL, Hoek KL, Howard LM, Allos TM, Niu X, Gordy LE, Creech CB, Hill H, Joyce S, Edwards KM, Link AJ (2017) Proteomics 17: Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine Efficacy by Modulating Host Immune Responses. Ahmad S, Bhattacharya D, Kar S, Ranganathan A, Van Kaer L, Das G (2019) Infect Immun 87: Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial. Howard LM, Hoek KL, Goll JB, Samir P, Galassie A, Allos TM, Niu X, Gordy LE, Creech CB, Prasad N, Jensen TL, Hill H, Levy SE, Joyce S, Link AJ, Edwards KM (2017) PLoS One 12: e0167488 Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. Sadagopal S, Braunstein M, Hager CC, Wei J, Daniel AK, Bochan MR, Crozier I, Smith NE, Gates HO, Barnett L, Van Kaer L, Price JO, Blackwell TS, Kalams SA, Kernodle DS (2009) PLoS One 4: e5531 Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL, Pandemic H1N1 Vaccine Adult Study Group (2012) Vaccine 30: 4240-8 Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P, Chang DZ, Courtney A, Sastry JK, Wang PG, Li C, Zhou D (2009) Vaccine 27: 3484-8 The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nakui M, Sekimoto M, Koda T (2000) Int Immunol 12: 987-94 NF-kappa B activation plays an important role in the IL-4-induced protection from apoptosis. Zamorano J, Mora AL, Boothby M, Keegan AD (2001) Int Immunol 13: 1479-87 Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A. Luan L, Patil NK, Guo Y, Hernandez A, Bohannon JK, Fensterheim BA, Wang J, Xu Y, Enkhbaatar P, Stark R, Sherwood ER (2017) Sci Rep 7: 40050 Update on active specific immunotherapy with melanoma vaccines. Conforti AM, Ollila DW, Kelley MC, Gammon G, Morton DL (1997) J Surg Oncol 66: 55-64 Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep. Fukuda S, Ihara K, Bohannon JK, Hernandez A, Patil NK, Luan L, Stothers C, Stark R, Prough DS, Herndon DN, Sherwood ER, Enkhbaatar P (2020) Shock 53: 307-316 Interleukin-1 beta and interferon-gamma regulate interleukin-6 production in cultured human intestinal epithelial cells. Parikh AA, Salzman AL, Fischer JE, Szabó C, Hasselgren PO (1997) Shock 8: 249-55 The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants. Bohannon JK, Hernandez A, Enkhbaatar P, Adams WL, Sherwood ER (2013) Shock 40: 451-62 Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le(a), sialyl Le(x), GD3 and GM2) better than soluble lysate cancer vaccine. Ravindranath MH, Bauer PM, Amiri AA, Miri SM, Kelley MC, Jones RC, Morton DL (1997) Anticancer Drugs 8: 217-24 Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Fissell WH, Dyke DB, Weitzel WF, Buffington DA, Westover AJ, MacKay SM, Gutierrez JM, Humes HD (2002) Blood Purif 20: 55-60
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.